Compounds > pnu 103017
Page last updated: 2024-11-13

pnu 103017

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

PNU 103017: an HIV aspartyl protease inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID54692909
CHEMBL ID2062136
SCHEMBL ID7352941
MeSH IDM0279465

Synonyms (20)

Synonym
pnu-103017
u-103017
4-cyano-n-[3-[cyclopropyl-(4-hydroxy-2-oxo-5,6,7,8,9,10-hexahydrocycloocta[b]pyran-3-yl)methyl]phenyl]benzenesulfonamide
166335-18-8
4-hydroxy-3-[3-(4-cyanomethylphenylsulfonamido)phenyl]cyclopropyl)methyl]-5,6,7,8,9,10-hexahydro-2h-cycloocta[b]pyran-2-one
u103017
pnu 103017
CHEMBL2062136
4-cyano-n-(3-(cyclopropyl(5,6,7,8,9,10-hexahydro-4-hydroxy-2-oxo-2h-cycloocta(b)pyran-3-yl)methyl )phenyl)benzenesulfonamide
benzenesulfonamide, 4-cyano-n-(3-(cyclopropyl(5,6,7,8,9,10-hexahydro-4-hydroxy-2-oxo-2h-cycloocta(b)pyran-3-yl)methyl )phenyl)-
4-cyano-n-(3-(cyclopropyl(5,6,7,8,9,10-hexahydro-4-hydroxy-2-oxo-2h-cycloocta(b)pyran-3-yl)methyl)phenyl)benzenesulfonamide
benzenesulfonamide, 4-cyano-n-(3-(cyclopropyl(5,6,7,8,9,10-hexahydro-4-hydroxy-2-oxo-2h-cycloocta(b)pyran-3-yl)methyl)phenyl)-
7iw8t16kfs ,
unii-7iw8t16kfs
SCHEMBL7352941
pnu-103017, (+/-)-
4-cyano-n-(3-(cyclopropyl(5,6,7,8,9,10-hexahydro-4-hydroxy-2-oxo-2h-cycloocta(b)pyran-3-yl)methyl)phenyl)-benzenesulfonamide
HY-19236
CS-0014977
AKOS040742430

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" While the use of currently approved HIV protease inhibitors in concert with drugs that target the reverse transcriptase has dramatically ameliorated the disease state for many individuals, highly-structured dosing regimens accompanied by adverse side-effect profiles have led to a significant level of patient non-compliance."( Non-peptidic HIV protease inhibitors.
Chrusciel, RA; Strohbach, JW, 2004)		0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Genome polyprotein Human rhinovirus sp.Ki0.00320.00010.01650.1000AID163812
Protease Human immunodeficiency virus 1IC50 (µMol)2.00000.00010.22487.3200AID162031; AID162048
Protease Human immunodeficiency virus 1Ki0.00090.00000.04433.1000AID160271; AID160296; AID160437; AID160467
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (44)

Assay IDTitleYearJournalArticle
AID162031Compound was evaluated for in vitro inhibition of human immunodeficiency virus type 1 (HIV-1) Protease1998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
Non-peptidic HIV protease inhibitors: C2-symmetry-based design of bis-sulfonamide dihydropyrones.
AID18007Bioavailability (F) was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 5 mg/kg dosage administered perorally in rats1995Journal of medicinal chemistry, Dec-22, Volume: 38, Issue:26
Structure-based design of sulfonamide-substituted non-peptidic HIV protease inhibitors.
AID20766Time of maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 5 mg/kg dosage administered perorally in rats1995Journal of medicinal chemistry, Dec-22, Volume: 38, Issue:26
Structure-based design of sulfonamide-substituted non-peptidic HIV protease inhibitors.
AID18616Oral bioavailability in rat (Sprague-Dawley) (male) (dose 5.1 mg/kg p.o.)1997Journal of medicinal chemistry, Mar-28, Volume: 40, Issue:7
Structure-based design of nonpeptidic HIV protease inhibitors: the sulfonamide-substituted cyclooctylpyramones.
AID23185Half-life was measured after intravenous administration of 2.5 mg/kg of drug in male Dawley rats1997Journal of medicinal chemistry, Mar-28, Volume: 40, Issue:7
Structure-based design of nonpeptidic HIV protease inhibitors: the sulfonamide-substituted cyclooctylpyramones.
AID14093Maximum concentration was measured after peroral administration of 5.1 mg/kg of drug in male Dawley rats1997Journal of medicinal chemistry, Mar-28, Volume: 40, Issue:7
Structure-based design of nonpeptidic HIV protease inhibitors: the sulfonamide-substituted cyclooctylpyramones.
AID160271Binding affinity against HIV-1 protease1997Journal of medicinal chemistry, Mar-28, Volume: 40, Issue:7
Structure-based design of nonpeptidic HIV protease inhibitors: the sulfonamide-substituted cyclooctylpyramones.
AID15672Total plasma clearance value was obtained after intravenous administration of 4.9 mg/kg of drug in male Beagle dogs1997Journal of medicinal chemistry, Mar-28, Volume: 40, Issue:7
Structure-based design of nonpeptidic HIV protease inhibitors: the sulfonamide-substituted cyclooctylpyramones.
AID23026The total body administered intravenously in dog1995Journal of medicinal chemistry, Dec-22, Volume: 38, Issue:26
Structure-based design of sulfonamide-substituted non-peptidic HIV protease inhibitors.
AID211499Median cell culture toxic dose was evaluated against H9 cell line1997Journal of medicinal chemistry, Mar-28, Volume: 40, Issue:7
Structure-based design of nonpeptidic HIV protease inhibitors: the sulfonamide-substituted cyclooctylpyramones.
AID78917Antiviral activity in HIV-1 infected H9 cells1997Journal of medicinal chemistry, Mar-28, Volume: 40, Issue:7
Structure-based design of nonpeptidic HIV protease inhibitors: the sulfonamide-substituted cyclooctylpyramones.
AID162048Tested for inhibition of HIV protease1996Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22
Structure-based design of HIV protease inhibitors: sulfonamide-containing 5,6-dihydro-4-hydroxy-2-pyrones as non-peptidic inhibitors.
AID15668Total plasma clearance value was obtained after intravenous administration of 2.5 mg/kg of drug in male Dawley rats1997Journal of medicinal chemistry, Mar-28, Volume: 40, Issue:7
Structure-based design of nonpeptidic HIV protease inhibitors: the sulfonamide-substituted cyclooctylpyramones.
AID23189Half-life was measured after intravenous administration of 4.9 mg/kg of drug in male Beagle dogs1997Journal of medicinal chemistry, Mar-28, Volume: 40, Issue:7
Structure-based design of nonpeptidic HIV protease inhibitors: the sulfonamide-substituted cyclooctylpyramones.
AID160437Tested for inhibition of HIV protease1996Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22
Structure-based design of HIV protease inhibitors: sulfonamide-containing 5,6-dihydro-4-hydroxy-2-pyrones as non-peptidic inhibitors.
AID1645897Oral bioavailability in rat2019European journal of medicinal chemistry, Jan-15, Volume: 162Pharmaceutical and medicinal significance of sulfur (S
AID14090Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 5 mg/kg dosage administered perorally in rats1995Journal of medicinal chemistry, Dec-22, Volume: 38, Issue:26
Structure-based design of sulfonamide-substituted non-peptidic HIV protease inhibitors.
AID14091Maximum concentration was measured after peroral administration of 10 mg/kg of drug in male Beagle dogs1997Journal of medicinal chemistry, Mar-28, Volume: 40, Issue:7
Structure-based design of nonpeptidic HIV protease inhibitors: the sulfonamide-substituted cyclooctylpyramones.
AID160467Inhibitory activity against HIV-1 protease1995Journal of medicinal chemistry, Dec-22, Volume: 38, Issue:26
Structure-based design of sulfonamide-substituted non-peptidic HIV protease inhibitors.
AID10921Area under the curve was determined after peroral administration of 5.1 mg/kg in mal Dawley rats1997Journal of medicinal chemistry, Mar-28, Volume: 40, Issue:7
Structure-based design of nonpeptidic HIV protease inhibitors: the sulfonamide-substituted cyclooctylpyramones.
AID23002Apparent volume of distribution was obtained after intravenous administration of 2.5 mg/kg of drug in male Dawley rats1997Journal of medicinal chemistry, Mar-28, Volume: 40, Issue:7
Structure-based design of nonpeptidic HIV protease inhibitors: the sulfonamide-substituted cyclooctylpyramones.
AID18614Oral bioavailability in dog (Beagle) (male) (dose 10 mg/kg p.o.)1997Journal of medicinal chemistry, Mar-28, Volume: 40, Issue:7
Structure-based design of nonpeptidic HIV protease inhibitors: the sulfonamide-substituted cyclooctylpyramones.
AID23025The steady-state volume of distribution was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 2.5 mg/kg administered intravenously dosage in rats1995Journal of medicinal chemistry, Dec-22, Volume: 38, Issue:26
Structure-based design of sulfonamide-substituted non-peptidic HIV protease inhibitors.
AID24093The half life time estimated was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 2.5 mg/kg dosage administered intravenously in rats1995Journal of medicinal chemistry, Dec-22, Volume: 38, Issue:26
Structure-based design of sulfonamide-substituted non-peptidic HIV protease inhibitors.
AID1645896Antiviral activity against CHIKV2019European journal of medicinal chemistry, Jan-15, Volume: 162Pharmaceutical and medicinal significance of sulfur (S
AID163812Binding affinity against HIV-2 protease1997Journal of medicinal chemistry, Mar-28, Volume: 40, Issue:7
Structure-based design of nonpeptidic HIV protease inhibitors: the sulfonamide-substituted cyclooctylpyramones.
AID1645915Inhibition of HIV protease2019European journal of medicinal chemistry, Jan-15, Volume: 162Pharmaceutical and medicinal significance of sulfur (S
AID20575Maximum time taken by the drug to reach peak concentration after peroral administration of 5.1 mg/kg of drug male in Dawley rats1997Journal of medicinal chemistry, Mar-28, Volume: 40, Issue:7
Structure-based design of nonpeptidic HIV protease inhibitors: the sulfonamide-substituted cyclooctylpyramones.
AID160296Compound was evaluated for in vitro inhibition of human immunodeficiency virus type 1 (HIV-1) Protease1998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
Non-peptidic HIV protease inhibitors: C2-symmetry-based design of bis-sulfonamide dihydropyrones.
AID10917Area under the curve was determined after intravenous administration of 4.9 mg/kg in male Beagle dogs1997Journal of medicinal chemistry, Mar-28, Volume: 40, Issue:7
Structure-based design of nonpeptidic HIV protease inhibitors: the sulfonamide-substituted cyclooctylpyramones.
AID20572Maximum time taken by the drug to reach peak concentration after peroral administration of 10 mg/kg of drug male in male Beagle dogs1997Journal of medicinal chemistry, Mar-28, Volume: 40, Issue:7
Structure-based design of nonpeptidic HIV protease inhibitors: the sulfonamide-substituted cyclooctylpyramones.
AID15701The total body administered intravenously in rats1995Journal of medicinal chemistry, Dec-22, Volume: 38, Issue:26
Structure-based design of sulfonamide-substituted non-peptidic HIV protease inhibitors.
AID10916Area under the curve was determined after intravenous administration of 2.8 mg/kg in male Dawley rats1997Journal of medicinal chemistry, Mar-28, Volume: 40, Issue:7
Structure-based design of nonpeptidic HIV protease inhibitors: the sulfonamide-substituted cyclooctylpyramones.
AID23006Apparent volume of distribution was obtained after intravenous administration of 4.9 mg/kg of drug in male Beagle dogs1997Journal of medicinal chemistry, Mar-28, Volume: 40, Issue:7
Structure-based design of nonpeptidic HIV protease inhibitors: the sulfonamide-substituted cyclooctylpyramones.
AID14089Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 10 mg/kg dosage administered perorally in dog1995Journal of medicinal chemistry, Dec-22, Volume: 38, Issue:26
Structure-based design of sulfonamide-substituted non-peptidic HIV protease inhibitors.
AID1645898Oral bioavailability in dog2019European journal of medicinal chemistry, Jan-15, Volume: 162Pharmaceutical and medicinal significance of sulfur (S
AID20765Time of maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 10 mg/kg dosage administered perorally in dog1995Journal of medicinal chemistry, Dec-22, Volume: 38, Issue:26
Structure-based design of sulfonamide-substituted non-peptidic HIV protease inhibitors.
AID10738Area under the curve was determined after intravenous administration of 10 mg/kg in male Beagle dogs1997Journal of medicinal chemistry, Mar-28, Volume: 40, Issue:7
Structure-based design of nonpeptidic HIV protease inhibitors: the sulfonamide-substituted cyclooctylpyramones.
AID18006Bioavailability (F) was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 10 mg/kg dosage administered perorally in dog1995Journal of medicinal chemistry, Dec-22, Volume: 38, Issue:26
Structure-based design of sulfonamide-substituted non-peptidic HIV protease inhibitors.
AID1645900Half life in dog2019European journal of medicinal chemistry, Jan-15, Volume: 162Pharmaceutical and medicinal significance of sulfur (S
AID1645899Half life in rat2019European journal of medicinal chemistry, Jan-15, Volume: 162Pharmaceutical and medicinal significance of sulfur (S
AID81594Antiviral potency of compound determined against human immunodeficiency virus type 11995Journal of medicinal chemistry, Dec-22, Volume: 38, Issue:26
Structure-based design of sulfonamide-substituted non-peptidic HIV protease inhibitors.
AID24094The half life time estimated was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 5 mg/kg dosage administered intravenously in dog1995Journal of medicinal chemistry, Dec-22, Volume: 38, Issue:26
Structure-based design of sulfonamide-substituted non-peptidic HIV protease inhibitors.
AID15700The total body administered intravenously in dog1995Journal of medicinal chemistry, Dec-22, Volume: 38, Issue:26
Structure-based design of sulfonamide-substituted non-peptidic HIV protease inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's7 (77.78)18.2507
2000's1 (11.11)29.6817
2010's1 (11.11)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.95

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.95 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.35 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.95)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (11.11%)5.53%
Reviews2 (22.22%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (66.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
urea
pseudourea: clinical use; structure. isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.		3.1210isourea;
monocarboxylic acid amide;
one-carbon compound		Daphnia magna metabolite;
Escherichia coli metabolite;
fertilizer;
flour treatment agent;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
delavirdine
Delavirdine: A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.. delavirdine : The amide resulting from the formal condensation of 5-[(methylsulfonyl)amino]-1H-indole-2-carboxylic acid and 4-amino group of 1-[3-(isopropylamino)pyridin-2-yl]piperazine, delavirdine is a non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. Viral resistance emerges rapidly when delavirdine is used alone, so it is therefore used (as the methanesulfonic acid salt) with other antiretrovirals for combination therapy of HIV infection.		210aminopyridine;
indolecarboxamide;
N-acylpiperazine;
sulfonamide		antiviral drug;
HIV-1 reverse transcriptase inhibitor
zidovudine
Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.		210azide;
pyrimidine 2',3'-dideoxyribonucleoside		antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
dmp 850
DMP 850: structure in first source		3.1210
tetronic acid
tetronic acid: structure; in fifth source		3.1210
e-6801
[no description available]		3.3110
phenprocoumon
Phenprocoumon: Coumarin derivative that acts as a long acting oral anticoagulant.. phenprocoumon : A hydroxycoumarin that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenylpropyl group.		2.3920hydroxycoumarinanticoagulant;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor
tipranavir
tipranavir: inhibits HIV-1 protease. tipranavir : A pyridine-2-sulfonamide substituted at C-5 by a trifluoromethyl group and at the sulfonamide nitrogen by a dihydropyrone-containing m-tolyl substituent. It is an HIV-1 protease inhibitor.		3.520sulfonamideantiviral drug;
HIV protease inhibitor
pd 178390
PD 178390: structure in first source		3.1210
ConditionIndicatedRelationship StrengthStudiesTrials
HIV
Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.		03.3220
HIV Coinfection
[description not available]		02.9310
HIV Infections
Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).		02.9310